Adler G, Pacuszka T, Lewartowska A, Rowinska E, Oblakowski P, Panasiewicz M
Department of Biochemistry, Medical Center of Postgraduate Education, Marymoncka 99, 01 813 Warsaw, Poland.
Lung Cancer. 2001 Dec;34(3):383-5. doi: 10.1016/s0169-5002(01)00264-1.
The characteristic feature of small cell lung cancer carcinoma (SCLC) is the aberrant expression and abundant presentation of fucosyl-GM1 ganglioside (FucGM1). In the present study we searched for the presence of anti-FucGM1 ganglioside, as well as anti-GM1, GM2 and GD3 ganglioside autoantibodies in the sera of patients with SCLC and as a control, in sera of patients with renal cell cancer (RC) and healthy blood donors. The autoantibodies against FucGM1 were present at low titer in only three of 36 SCLC patients, and with similar titer in two of 36 RC patients and four of 36 healthy controls. Likewise, the autoantibodies against GM2 and GM3 gangliosides were found only sporadically and with the same titer and frequency in cancer patients as in healthy persons. Anti-GD3 autoantibodies could not be detected in any of the screened sera.
小细胞肺癌（SCLC）的特征性表现是岩藻糖基-GM1神经节苷脂（FucGM1）的异常表达和大量呈现。在本研究中，我们检测了SCLC患者血清中抗FucGM1神经节苷脂以及抗GM1、GM2和GD3神经节苷脂自身抗体的存在情况，并以肾细胞癌（RC）患者血清和健康献血者血清作为对照。仅36例SCLC患者中的3例血清中存在低滴度的抗FucGM1自身抗体，36例RC患者中的2例以及36例健康对照中的4例血清中抗FucGM1自身抗体滴度与之相似。同样，抗GM2和GM3神经节苷脂自身抗体仅偶尔被发现，且在癌症患者和健康人中的滴度及出现频率相同。在所有筛查血清中均未检测到抗GD3自身抗体。
